Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 2 boards, counting each seat separately. Longest: Aprea Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Aprea Therapeutics Inc. June 16, 202693.4%
-
Aprea Therapeutics Inc. August 23, 202393.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Aprea Therapeutics Inc. | Grant or award | +3,135 | — | — |
| Feb 12, 2026 | Oncolytics Biotech Inc. | Open-market purchase | +40,000 | $0.85 | $34,000 |
| Feb 11, 2026 | Oncolytics Biotech Inc. | Open-market purchase | +60,000 | $0.83 | $49,800 |
| Jan 16, 2026 | Oncolytics Biotech Inc. | Open-market purchase | +100,000 | $1.04 | $104,000 |
| Jun 5, 2025 | Aprea Therapeutics Inc. | Grant or award | +1,045 | — | — |
| Oct 11, 2024 | Aprea Therapeutics Inc. | Open-market purchase | +10,000 | $2.68 | $26,800 |
| Jun 20, 2024 | Aprea Therapeutics Inc. | Grant or award | +1,045 | — | — |
| Mar 13, 2024 | Aprea Therapeutics Inc. | Open-market purchase | +6,860 | $7.29 | $50,009 |
| Aug 23, 2023 | Aprea Therapeutics Inc. | Grant or award | +500 | — | — |
| Jun 7, 2023 | Aprea Therapeutics Inc. | Open-market purchase | +6,029 | $3.68 | $22,187 |
| Jun 6, 2023 | Aprea Therapeutics Inc. | Open-market purchase | +4,068 | $3.63 | $14,767 |
Questions about Bernd R. Seizinger
What boards is Bernd R. Seizinger on?
Bernd R. Seizinger sits on the boards of Aprea Therapeutics Inc. and Oncolytics Biotech Inc.
How long has Bernd R. Seizinger served on boards?
Our records show at least 4 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.